Shilpa Gupta, MD, on Locally Advanced/Metastatic Urothelial Cancer: Phase III MAIN-CAV Trial
ASCO 2026
Shilpa Gupta, MD, of Taussig Cancer Institute, discusses findings from the phase III MAIN-CAV study (Alliance A032001) of maintenance cabozantinib and avelumab vs avelumab after first-line platinum-based chemotherapy in patients with locally advanced/metastatic urothelial cancer (Abstract 4514).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
In locally advanced and metastatic urothelial cancer, platinum based chemotherapy has been the standard of care for decades until recently when EV pembro showed that it was better than platinum in the frontline setting. Back in 2020, maintenance avelumab was approved for patients who did not progress on frontline platinum based chemotherapy and it improved survival compared to best supportive care. We wanted to build upon the avelumab backbone to see if we can help patients who don't have durable response and we designed this cooperative group trial to build on avelumab backbone with a VEGF TKI, cabozantinib or the MAIN-CAV trial was built on that. It was a very timely study at the time. We designed it to enroll 654 patients and randomized them to maintenance avelumab versus maintenance avelumab and cabozantinib, limiting the total duration of two years for each arm. Primary endpoint was overall survival and we hypothesized that we could build upon the median 21 month overall survival with the avelumab to 28 months with combination. And while the planned enrollment was for 654 patients, unfortunately we could not accrue the patient because of the new standard with EV and pembro. So we closed the trial after 68 patients were enrolled because EV pembro was approved in the US and we analyzed the patients enrolled and we found that you know 33 and 35 patients were enrolled in avelumab versus avelumab cabozantinib arm. Unfortunately we did not see differences in the progression-free survival or overall survival. But this is an underpowered study which was closed prematurely. So it's difficult to make that determination. But in the limited numbers we have, we did not see a difference and we did not see that cabozantinib even added to the response rate seen when avelumab. As far as toxicities were concerned, there were no new safety signals and there was more toxicity in the combination arm as expected with an IO and TKI. So at this time, we are working on the translational work for this study to guide future development around VEGF.
The ASCO Post Staff
Misty Dawn Shields, MD, PhD, of Indiana University Melvin and Bren Simon Comprehensive Cancer Center, shares her perspective on two small cell lung cancer (SCLC) abstracts presented at this year’s meeting. The first focuses on a post hoc analysis of the phase III DeLLphi-304 trial (Abstract 8006), which looked at the intracranial efficacy of tarlatamab in the second line; the second evaluated concurrent thoracic radiotherapy, chemotherapy, and durvalumab in extensive-stage disease (Abstract LBA8005).
The ASCO Post Staff
Ronald C. Chen, MD, MPH, FASCO, of the University of Kansas Medical Center, presents health-related quality of life (HRQoL) data from the AMBASSADOR trial, which showed that in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, adjuvant pembrolizumab for 1 year approximately doubled disease-free survival, causes fatigue and dyspnea which modestly impacted physical function and ability to perform certain roles (such as work and hobbies), without impact on overall quality of life (Abstract 4513).
The ASCO Post Staff
Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses safety results for DESTINY-Gastric03 Part 2 (arms D and F) and Part 4. The trial evaluated first-line fam-trastuzumab deruxtecan-nxki–based regimens in advanced HER2-expressing gastric cancer, gastroesophageal adenocarcinoma, and esophageal carcinoma (Abstract 4002).
Suneel Kamath, MD, of Cleveland Clinic, discusses a study that found tissue tumor mutation burden (TMB) was a stronger predictor of immunotherapy outcomes than blood-based circulating tumor DNA testing, with high tissue TMB associated with a longer time to treatment failure (Abstract 2580).
The ASCO Post Staff
John M. Burke, MD, of SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, presents findings from the phase III frontMIND trial, which evaluated tafasitamab plus lenalidomide and R-CHOP in patients newly diagnosed with diffuse large B-cell lymphoma (Abstract LBA7000).